Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by itntdfon Jan 18, 2024 12:29pm
211 Views
Post# 35833861

some color behind pancan strategic reevaluation

some color behind pancan strategic reevaluation

After four years of operation, PanCAN underwent a strategic re-evaluation of Precision Promise in late 2023. It was a good time to evaluate the program to determine if there were opportunities to continue to innovate the study. While the study has been successful, we also wanted to see if there were ways to be more efficient.

The financial model for Precision Promise was dependent on a steady stream of new
investigational agents coming into the study. The last year has been a challenging
economic environment for pharma and biotech companies. So, we wanted to evaluate if a
collaboration or alliance with another organization could stabilize the financial model
by streamlining operations and efficiencies while still accomplishing the study
objectives. We are excited to announce that PanCAN made a strategic decision to
collaborate with GCAR (Global Coalition for Adaptive Research) and take advantage of the
strengths of both organizations to pursue the long-term sustainability of a new
pancreatic cancer clinical trial platform for patients.

The goals of the alliance are increased efficiency and scalability with GCAR sponsoring
the study and overseeing the operations, and PanCAN providing disease expertise and
relationships with the pancreatic cancer community. It brings together the strengths of
both organizations for patient benefit.

About Global Coalition for Adaptive Research
The Global Coalition for Adaptive Research (GCAR) unites physicians, clinical researchers, advocacy and philanthropic organizations, biotech/pharma, health authorities, and other key stakeholders in healthcare to expedite the discovery and development of treatments for patients with rare and deadly diseases. As Sponsor of innovative trials, including master protocols and adaptive platform trials, GCAR is dedicated to the advancement of science by modernizing clinical trials that support more efficient, less costly drug development. Adaptive platform trials deliver an unmatched accelerated time from discovery in the lab to implementation in the clinic resulting in better treatments and lives saved. To learn more about GCAR and its initiatives, visit gcaresearch.org.
 

<< Previous
Bullboard Posts
Next >>